Best Melanotan 2 5mg and 10mg Peptides GMP Factory

Melanotan 2 Powder

Melanotan 2 Powder

specification: Melanotan 2 5MG, Melanotan 2 10MG

Peptide.ltd has more than 20 years of peptides R&D and production technology, we can provide 1000+ multiple peptides, from “mg” to “gram” which is suitable for a variety of research fields, bulk quantities available also. We provide professional customization services with fast delivery. Some products can provide DMF certificates.

Production Capacity: Provide Customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Melanotan 2 Peptide Dosage Calculator

Referenced Citations

[1] Wessells H, Levine N, Hadley ME, Dorr R, Hruby V.  Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391.

[2] Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930.

[3] M. M. Sirufo, L. M. Magnanimi, L. Ginaldi, and M. De Martinis, “Anorexia nervosa and autoimmune comorbidities: A bidirectional route?,” CNS Neurosci. Ther., vol. 28, no. 12, pp. 1921–1929, Sep. 2022, doi: 10.1111/cns.13953.

[4] Li G, Zhang Y, Wilsey JT, Scarpace PJ. Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression. J Endocrinol. 2004 Jul;182(1):123-32. doi: 10.1677/joe.0.1820123. PMID: 15225137.

[5] Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014;48(1):47-51. doi:10.1016/j.npep.2013.11.001.

[6] Hjuler, K. F., & Lorentzen, H. F. (2014). Melanoma associated with the use of melanotan-II. Dermatology (Basel, Switzerland), 228(1), 34–36.

[7] J. K. van den Heuvel et al., “Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets,” Front. Behav. Neurosci., vol. 9, p. 358, Dec. 2015, doi: 10.3389/fnbeh.2015.00358.

[8] Zhang Y, Collazo R, Gao Y, Li G, Scarpace PJ. Intermittent MTII application evokes repeated anorexia and robust fat and weight loss. Peptides. 2010;31(4):639-643. doi:10.1016/j.peptides.2009.12.019.

[9] Han D, Wang Y, Chen J, Zhang J, Yu P, Zhang R, Li S, Tao B, Wang Y, Qiu Y, Xu M, Gao E, Cao F. Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury. J Pineal Res. 2019 Aug;67(1):e12571. doi: 10.1111/jpi.12571. Epub 2019 Apr 12. PMID: 30903623.

[10] Wang W, Guo DY, Lin YJ, Tao YX. Melanocortin Regulation of Inflammation. Front Endocrinol (Lausanne). 2019;10:683. Published 2019 Oct 9. doi:10.3389/fendo.2019.00683.

[11] ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (2021).

[12] Krashes, M. J., Lowell, B://. B., & Garfield, A. S. (2016). Melanocortin-4 receptor-regulated energy homeostasis. Nature neuroscience, 19(2), 206–219.

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine. The author of this article does not encourage any purchase of Melanotan II. If you have any purchase needs, please seek help from the customer service representative.

Scientific Journal paper Author:
  1. Mariël P Ter Laak 

Department of Medical Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands

  1. Joakim Riikonen

Department of Physics and Mathematics, University of Eastern Finland, Kuopio, Finland

  1. Ryouichi Banno

Department of Metabolic Diseases, Field of Internal Medicine, Nagoya University Graduate School of Medicine

  1. Hiroshi Arima

Department of Metabolic Diseases, Field of Internal Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Institute of Pharmacology, Russian Academy of Medical Sciences, 8 Baltiyskaya Street, 125315 Moscow, Russia

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. peptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.